IBIO, INC. Debt Securities, Available-for-sale, Realized Gain (Loss)
IBIO, INC. (IBIO) reported Debt Securities, Available-for-sale, Realized Gain (Loss) of $0 for the 3-month period ending 2023-12-31, per its 10-Q filed 2024-02-09.
Discontinued › Income Statement › Other Income
us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss · last filed 2024-02-09
- IBIO, INC. debt securities, available-for-sale, realized gain (loss) for the quarter ending 2023-12-31 was $0.00.
- IBIO, INC. debt securities, available-for-sale, realized gain (loss) for the quarter ending 2023-09-30 was $0.00.
- IBIO, INC. debt securities, available-for-sale, realized gain (loss) for the quarter ending 2022-12-31 was $0.00.
- IBIO, INC. debt securities, available-for-sale, realized gain (loss) for the quarter ending 2022-09-30 was $0.00.
| Period end | Debt Securities, Available-for-sale, Realized Gain (Loss) 3 month | Debt Securities, Available-for-sale, Realized Gain (Loss) 6 month |
|---|---|---|
| 2023-12-31 | $0.00 10-Q · filed 2024-02-09 | $0.00 10-Q · filed 2024-02-09 |
| 2023-09-30 | $0.00 10-Q · filed 2023-11-14 | |
| 2022-12-31 | $0.00 10-Q · filed 2024-02-09 | $0.00 10-Q · filed 2024-02-09 |
| 2022-09-30 | $0.00 10-Q · filed 2023-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |